cse new listings

CSE Bulletin: New Listing - Levitee Labs Inc.

The common shares of Levitee Labs Inc. have been approved for listing on the CSE.

Listing and disclosure documents will be available at www.thecse.com on the trading date.

Levitee Labs is a functional mushrooms company. Within the functional mushrooms space, Levitee Labs is focused on the development and sale of high potency mushroom extract nutraceuticals and supplies and equipment for mushroom cultivation.

_________________________________

Les actions ordinaires de Levitee Labs Inc. ont été approuvées pour inscription à la CSE.

Les documents de cotation et d'information seront disponibles sur www.thecse.com à la date de négociation.

Levitee Labs est une entreprise de champignons fonctionnels. Dans l'espace des champignons fonctionnels, Levitee Labs se concentre sur le développement et la vente de nutraceutiques d'extraits de champignons à haute puissance et de fournitures et équipements pour la culture des champignons.

Issuer/Émetteur: Levitee Labs Inc.
Security Type/Titre: Common Shares/Actions ordinaires
Symbol(s)/Symbole(s): LVT
Number of securities issued and outstanding/ Titres émis et en circulation: 80 112 564
Number of Securities reserved for issuance/ Titres réservés pour émission: 18 957 485
CSE Sector/Catégorie: Life Sciences/Sciences Biologiques
CUSIP: 527424 10 5
ISIN: CA 527424 10 5 1
Boardlot/Quotité: 500
Trading Currency/Monnaie de négociation: CDN$/$CDN
Trading Date/Date de negociation: le 21 juillet/July 2021
Other Exchanges/Autres marches: N/A
Fiscal Year end /Clôture de l'exercice financier: le 30 septembre/September
Transfer Agent/Agent des transferts: Odyssey Trust Company

 

The Exchange is accepting Market Maker applications for LVT. Please email: Trading@theCSE.com

If you have any questions or require further information please contact Listings at (416) 367-7340 or E-mail: Listings@thecse.com

Pour toute question, pour obtenir de l'information supplémentaire veuillez communiquer avec le service des inscriptions au 416 367-7340 ou par courriel à l'adresse: Listings@thecse.com

News Provided by Newsfile via QuoteMedia

The Conversation (0)
Levitee Labs

Levitee Labs

Transforming the Traditional Landscape of Mental Health, Addiction Treatment and Pain Management Treatment Across Multiple Verticals

Transforming the Traditional Landscape of Mental Health, Addiction Treatment and Pain Management Treatment Across Multiple Verticals Keep Reading...
Numinus Wellness Announces Change of Auditor

Numinus Wellness Announces Change of Auditor

Numinus Wellness Inc. (TSX: NUMI) (OTCQB: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, announces that Davidson & Company LLP ("Davidson") has resigned as... Keep Reading...
Lobe Sciences Ltd. to Attend the ArcStone-Kingswood Growth Summit 2025 in Toronto

Lobe Sciences Ltd. to Attend the ArcStone-Kingswood Growth Summit 2025 in Toronto

lobe sciences ltd. (CSE: LOBE,OTC:LOBEF) (OTCQB: LOBEF) (FSE: LOBE.F) ("Lobe Sciences" or the "Company") a clinical stage biopharmaceutical company focused on developing products to treat diseases with significant unmet medical needs is pleased to announce its participation in the upcoming... Keep Reading...
Dried mushrooms and capsules aligned on a light surface.

Psychedelics Market Update: H1 2025 in Review

The market for psychedelic drugs is emerging as a strategic investment opportunity in healthcare, with forecasts generally placing its value at around US$6.4 billion in 2025. This burgeoning sector is set for robust, double-digit compound annual growth, significantly driven by North America,... Keep Reading...
Glowing mushrooms with colorful graphs in the background on a dark surface.

US Policy Momentum, Clinical Progress Fueling Psychedelics Market in 2025

When the US Food and Drug Administration (FDA) rejected Lykos Therapeutics’ new drug application for MDMA-assisted therapy last August, the initial disappointment cast a shadow over the psychedelics industry. However, the sector is seeing a resurgence of optimism in 2025 on the back of various... Keep Reading...
AVECHO BIOTECHNOLOGY

Avecho and Sandoz enter Exclusive License and Development Agreement to Commercialise CBD for Insomnia in Australia

Avecho Biotechnology Limited (ASX: AVE) (“Avecho” or the “Company”) today announced it has signed an exclusive ten-year development and licensing agreement with Sandoz Group AG (“Sandoz”) for the commercial rights to Avecho’s Phase III cannabidiol (“CBD”) capsule for insomnia in Australia.... Keep Reading...

Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025

Compass management will host a conference call at 8:00 am ET (1:00pm UK) Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the fourth... Keep Reading...

Latest Press Releases

Related News